Breast Cancer Treatment Guidelines

Overview and Approach

The National Comprehensive Cancer Network (NCCN) provides comprehensive, evidence-based recommendations for the management of breast cancer across all stages, with treatment decisions primarily based on tumor biology, disease extent, and patient factors 1, 2
The primary goals of systemic treatment for recurrent/stage IV breast cancer are palliating symptoms, prolonging survival, and maintaining or improving quality of life 2, 3
Treatment decisions should be made through a multidisciplinary team approach, integrating medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy 1, 4
The NCCN strongly encourages patient participation in clinical trials at all stages of breast cancer treatment 2, 5

Comprehensive pathology reporting is essential, including determination of histologic type, hormone receptor status, HER2 status, tumor grade, size, and lymph node involvement 1, 2
For metastatic disease, biopsy of accessible metastatic lesions is recommended to confirm diagnosis and reassess biological markers 3

For hormone receptor-positive, HER2-negative breast cancer, adjuvant endocrine therapy is recommended to reduce recurrence risk 1
For HER2-positive breast cancer, HER2-directed therapy should be offered to all patients 4
For triple-negative breast cancer, chemotherapy is the mainstay of treatment 3

Preoperative systemic therapy can facilitate breast conservation, render inoperable tumors operable, and provide prognostic information based on response to therapy 6, 7, 8
Ideal candidates for preoperative therapy include patients with inoperable breast cancer, HER2-positive disease, or triple-negative breast cancer ≥cT2 or ≥cN1 7, 8

For early-stage disease, options include breast-conserving surgery with radiation therapy or mastectomy with or without reconstruction 9
For patients with metastatic disease and intact primary tumor, the primary approach is systemic therapy, with surgery considered for palliation of symptoms or impending complications 2, 3

For patients with ER-low positive (1-10%) tumors, individualized consideration of risks versus benefits of endocrine therapy is recommended 1
Older patients should not be denied effective therapy based solely on age 3, 4

Evaluation of response to therapy should occur every 2-4 months for endocrine therapy and after 2-4 cycles for chemotherapy in metastatic setting 3
Regular clinical assessments should be performed during follow-up to provide optimal symptom management and maintain quality of life 4